OBJECTIVES: Recent analyses establish that heart transplantation is increasing among adults with congenital heart disease (ACHD), but the effects of pretransplant mechanical circulatory support (MCS) on perioperative and post-transplant outcomes have not been examined in the ACHD population.
INTRODUCTION
Improved survival to adulthood has resulted in dramatic increases in the prevalence of adult congenital heart disease (ACHD), and adults with congenital heart disease (CHD) now outnumber children [1] . Late sequelae of unoperated, palliated or repaired CHD include valvular dysfunction, significant arrhythmias and ventricular dysfunction. After other medical and interventional options are exhausted, many patients are referred for heart transplantation [2] . Mechanical circulatory support (MCS) as a bridge to transplant has become an increasingly utilized pathway for symptomatic patients awaiting orthotopic heart transplant (OHT), but may have been underutilized in the ACHD population [3] . Prior analyses of OHT in ACHD are dated [4] or have not specifically analysed the role of MCS in outcomes [5] .
We sought to perform a contemporary analysis of outcomes of OHT in ACHD patients, with a particular focus on comparing outcomes in patients bridged with MCS versus outcomes in patients not bridged with MCS.
MATERIALS AND METHODS
The Stanford University Institutional Review Board granted an exemption from review because this analysis uses deidentified data. Transplantation and post-transplant survival data were obtained using comprehensive datasets from the Organ Procurement and Transplantation Network (OPTN) through the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, wait-listed candidates and transplant recipients from all transplant centres in the USA, submitted by members of the OPTN under the oversight of the Health Resources and Services Administration, US Department of Health and Human Services. Datasets from the OPTN and SRTR were supplied by the Minneapolis Medical Research Foundation pursuant to HSRA contract number HHSH250201000018C. The authors alone were responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the US Government.
All recipients of OHT between 30 September 1987 and 1 September 2012 were included for analysis. Heart-lung transplants were excluded. Follow-up information was available through 2 September 2012. The primary population of interest included adults (defined at a recipient age of 18 years or greater at the time of transplant), but paediatric recipient statistics were calculated for comparison. Adult heart transplant recipients were classified based on primary diagnosis codes and the presence of prior congenital heart surgery as CHD or non-CHD. The use of pretransplant MCS was recorded from data variables recorded for the presence or absence of MCS at the time of transplant as well as descriptive variables recording the device or devices used, and each patient was classified as MCS or non-MCS. Short-term circulatory support in the form of intra-aortic balloon pump and extracorporeal membrane oxygenation were not included as MCS. Descriptive, perioperative and outcome variables were compared between the MCS and non-MCS groups.
After initial analysis resulted in a finding of no difference in adverse outcomes or survival, a post hoc subgroup analysis was performed to explore whether this finding was confounded by the fact that the MCS group was sicker at baseline. We compared the MCS group (n = 83) with a subset of non-MCS patients (n = 83) matched on the baseline variables that had proved significantly different between the original groups. Using a previously described SAS greedy matching macro [6] 
Statistical analysis
Baseline characteristics and outcome variables were compared using Fisher's exact test or the Wilcoxon test, as appropriate. Survival analysis was performed using Kaplan-Meier curves and the log-rank test for inter-group survival comparison. Trends over time were examined using a Mann-Kendall test for trend (a nonparametric test to determine the presence and direction of a trend over time [7] ). Unless otherwise specified, all tests were twotailed with a predetermined alpha for statistical significance of 0.05. Analyses were performed using Microsoft Excel (version 2010, Microsoft Corporation, Redmond, WA, USA) and SAS 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
During the study period, of the 54 102 patients who underwent heart transplant, 47 160 (87.2%) were adults. Of these, 1213 (2.6%) had a primary diagnosis of CHD. The proportion of ACHD transplants relative to all adult transplants increased over time (Fig. 1 , test for trend P < 0.001). MCS was used in 83 patients (6.8%). For comparison purposes, MCS was used in 8625 (19.3%) of 44 734 adults without CHD, and in 126 (3.7%) of 3426 children with CHD.
The proportion of ACHD transplant patients supported with MCS as a fraction of all ACHD transplants increased over time (Fig. 2 , test for trend P < 0.001). Thirty-day mortality by year of transplant among all ACHD patients decreased over the study period (Fig. 3 , test for trend P < 0.001).
The characteristics of the MCS and non-MCS groups of ACHD patients are given in Table 1 . Patients in the MCS group were more likely to be male, have had a prior sternotomy and on average had a higher serum creatinine and pulmonary capillary wedge pressure at listing. MCS patients spent fewer days on the waiting list, but were more likely to be in the hospital, in the ICU, on a ventilator or status 1A at the time of transplant. Within the MCS group, 67 (80.7%) were supported with a left ventricular assist device, 5 (6.0%) were supported with a right ventricular assist device, 6 (7.2%) were supported with both left and right ventricular assist devices and 5 (6.0%) were supported with the total 
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artificial heart. Of left ventricular assist devices used, 33 (49.2%) were pulsatile and 34 (50.7%) were continuous flow.
Outcomes of transplantation in the MCS and non-MCS groups are given in Table 2 . While the MCS group was more likely to receive a transfusion and had a longer average length of stay, other postoperative complications were not different between groups. Both groups of ACHD patients had greater short-term mortality than all adult recipients (6.3%). No differences were observed between the MCS group and non-MCS group in shortterm survival (30-day mortality 10.8% in MCS vs 13.5% in non-MCS, P = 0.62) or overall survival by Kaplan-Meier analysis (Fig. 4 , log-rank P = 0.57). Table 3 shows results of the post hoc subgroup comparison between the MCS group and the well-matched non-MCS subgroup. Matching resulted in no differences in key baseline characteristics, which had been present in the non-MCS group overall. Outcomes were no different between groups, except for a greater likelihood of transfusion in the MCS group. There were no differences in shortterm survival (30-day mortality 10.8% in MCS vs 8.4% in non-MCS, P = 0.60) or overall survival by Kaplan-Meier analysis (Fig. 5 , log-rank P = 0.29).
DISCUSSION
Our study confirms that ACHD is an increasingly common indication for OHT, relative to non-CHD diagnoses, and that MCS is increasingly utilized in the ACHD population. The principal finding of this study is that despite being sicker at baseline, no outcome differences or differences in survival were observed in those bridged to transplant with MCS compared with those who underwent OHT without prior MCS. There was a trend towards longer graft ischaemic time in the MCS group (P = 0.06), which might reflect additional time needed to explant the device. But without more extensive information available on the underlying congenital anatomy and number and nature of prior operative interventions, it is difficult to separate this effect from a possible effect of anatomic complexity or difficulty of dissection.
Because of the recent finding that MCS results in improved post-transplant survival in the broader population of adult transplant recipients [8] , we performed a subgroup analysis to compare the MCS group with a matched subgroup of non-MCS patients with a similar baseline risk profile. No differences in outcomes were apparent between these groups, except for a greater likelihood of transfusion in the MCS group.
Our analysis includes the finding that short-term (30-day) posttransplant mortality for ACHD patients steadily decreased over the study period (Fig. 3) . This differs from a previous analysis of transplant outcomes in ACHD, which found that unlike the overall population of adult recipients, mortality had not improved over time in the ACHD group [5] . Two differences in methodology likely explain the difference in findings. First, the prior study used the Nationwide Inpatient Sample, an administrative database that captures all inpatient admissions from a 20% stratified sample of non-federal hospitals in the USA. As such, their analysis was based on only a subset of all transplants, unlike that of this analysis, which uses the comprehensive SRTR registry. Secondly, their analysis used a before-and-after method of era comparison, with the dividing line of 1999 separating the two groups. We believe that a year-by-year method provides a more rigorous way of assessing a trend over time. We were able to perform this only for the entire ACHD group; relatively small numbers in the MCS group alone preclude a mortality analysis by year. Since the occurrence of transplantation while receiving MCS selects for patients who survive long enough to undergo a transplant, the MCS group in this study will not reflect several related groups: those in whom initiation of MCS is intended as a bridge to transplant, but who do not survive the placement of MCS; those who survive the placement of MCS but subsequently decompensate before transplant can occur; those who convert to destination therapy after initiation of MCS; and those who are converted to the 'bridge to recovery' status and are weaned from MCS without transplant. Quantification of the relative sizes of these groups will depend on results of other registry-based investigations.
It is encouraging, though, that MCS patients had no worse posttransplant outcomes or survival. This analysis supports the contention that current practices for the selection of patients who would benefit from the MCS pathway are not resulting in worsened posttransplant outcomes.
It is a limitation of this analysis that we do not have comparative information about the timing of decisions about initiating MCS Figure 4 : Kaplan-Meier curves for the MCS group (red) and the non-MCS group (blue) compared with all adult transplants (gray). Both the MCS group and non-MCS groups had worse survival compared with all adult transplants (log-rank P < 0.001 for both), but the MCS group did not differ from the non-MCS group (log-rank P = 0.57). 
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relative to clinical and haemodynamic status. At our institution, our recent practice has leant towards early institution of MCS with aggressive listing for transplantation. As we feel that the long-term outcomes of MCS patients are no worse than those of patients who do not receive VADs, we have increasingly adopted early VAD support as a bridge to transplantation. Further studies that do have information on clinical and haemodynamic variables in relation to clinical decision-making and outcomes are needed before a definitive practice paradigm can be recommended in regard to pathway decisions, patient selection and timing. A second major limitation is the heterogeneous nature of ACHD and the limited information available from the SRTR dataset about a patient's underlying lesion, prior repairs and current anatomical and haemodynamic parameters. Certain subsets of ACHD patients have been demonstrated in small series to be high risk at the time of OHT, particularly patients with failing Fontan/single ventricle physiology [9] [10] [11] , pulmonary hypertension [4] and those in whom prior pulmonary artery reconstruction had been performed [12] .
While further studies will be required to elucidate further the implications of this heterogeneity for decision-making about the use of MCS and timing of transplant in ACHD patients, the results of this study are encouraging in that the observed trends of increasing transplantation in ACHD and increasing use of MCS as a bridge to transplant have not been accompanied by any comparatively unfavourable outcomes. As ACHD continues to comprise a growing fraction of the transplant population, the OPTN registry may need structural revisions to adequately capture relevant data variables about ACHD patients that have important bearings on their transplant course and outcomes.
